Teva Reports Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Teva Pharma (TEVA) PT Lowered to $9 at Cowen
August 7, 2019 11:14 AM EDTCowen analyst Ken Cacciatore lowered the price target on Teva Pharma (NYSE: TEVA) to $9.00 (from $16.00) while maintaining a Market Perform rating.
The analyst commented, "Teva continues to perform as well as can be expected, with good cost reductions while still investing in Austedo & Ajovy.... More
Teva Pharma (TEVA) Tops Q2 EPS by 3c, Reaffirms Guidance
August 7, 2019 7:01 AM EDTTeva Pharma (NYSE: TEVA) reported Q2 EPS of $0.60, $0.03 better than the analyst estimate of $0.57. Revenue for the quarter came in at $4.3 billion versus the consensus estimate of $4.25 billion.
Full year 2019 revenues and EPS guidance reaffirmedFor earnings history and earnings-related data on Teva Pharma (TEVA) click here.
... More